⚕️ The information below is for educational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
GLP-1 receptor agonists — semaglutide, liraglutide, dulaglutide — are approved in India for two separate purposes: managing Type 2 diabetes and treating obesity or overweight. Many Indians are confused about which indication applies to them, what doses are used, and whether they need different monitoring.
Consult your healthcare provider before starting any medication.
This guide cuts through the confusion and explains exactly how GLP-1 use differs between these two conditions in the Indian context.
GLP-1 (glucagon-like peptide-1) receptor agonists mimic a gut hormone released after eating. They:
These overlapping mechanisms mean the same class of drugs works for both diabetes and weight management — but with important differences in goals, doses, monitoring, and duration.
Adults with Type 2 diabetes (T2DM) who need better blood sugar control, typically when:
| Drug | Brand | Dose for Diabetes | Route |
|---|---|---|---|
| Semaglutide | Ozempic | 0.5mg or 1mg weekly | Subcutaneous injection |
| Semaglutide oral | Rybelsus | 3mg → 7mg → 14mg daily | Oral tablet |
| Liraglutide | Victoza | 1.2mg or 1.8mg daily | Subcutaneous injection |
| Dulaglutide | Trulicity | 0.75mg or 1.5mg weekly | Subcutaneous injection |
| Exenatide | Byetta | 5–10mcg twice daily | Subcutaneous injection |
Adults who are:
| Drug | Brand | Dose for Weight Loss | Notes |
|---|---|---|---|
| Semaglutide 2.4mg | Wegovy | Up to 2.4mg weekly | CDSCO approved; limited availability in India |
| Liraglutide 3mg | Saxenda | Up to 3mg daily | Available; approximately Rs 12,000–15,000 per month |
| Semaglutide | Ozempic | 0.5–1mg weekly | Often used off-label for weight management |
Important for Indian users: Wegovy (semaglutide 2.4mg) has received CDSCO approval but availability remains limited to select metros. Many endocrinologists prescribe Ozempic off-label for weight management. This is a legal and common practice — but it must be done under medical supervision, not self-prescribed.
| Factor | Diabetes Use | Weight Loss Use |
|---|---|---|
| Primary goal | Lower HbA1c | Reduce body weight |
| Typical doses | Lower (0.5–1mg sema weekly) | Higher (up to 2.4mg sema weekly) |
| Weight loss expected | 3–6kg (secondary) | 10–15% body weight (primary) |
| Usual duration | Often lifelong | 12–24 months, then reassess |
| Insurance coverage | More likely covered | Rarely covered in India |
| Co-prescription | Often with metformin, SGLT-2 inhibitors | Often as monotherapy |
| HbA1c monitoring | Every 3 months | Annually (or if symptoms arise) |
| Hypoglycaemia risk | Higher (especially with insulin or sulphonylurea) | Low in non-diabetic users |
| BP monitoring | Standard | Closer — weight loss affects BP |
GLP-1 medications are not interchangeable without medical supervision. The dose, drug choice, and monitoring differ significantly. A diabetes dose may be insufficient for meaningful weight loss; a weight-loss dose in someone on insulin may cause dangerous hypoglycaemia.
Ozempic is licensed for diabetes in India. Using it for weight loss is off-label. This is not inherently unsafe — your doctor can legally prescribe it off-label — but it should never be self-prescribed based on online advice or social media.
GLP-1 medications manage diabetes effectively — they do not cure it. Stopping the medication typically causes HbA1c to rise back toward baseline within weeks to months.
Higher doses significantly increase the risk of nausea, vomiting, and treatment discontinuation. Titration (starting at a low dose and increasing slowly over months) is the standard protocol for a reason. Rushing titration is one of the leading causes of GLP-1 discontinuation in India.
Doses are individualised based on indication, kidney function, tolerance, and co-medications. Never self-adjust based on another person's prescription.
| Drug | Indication | Approx Monthly Cost |
|---|---|---|
| Ozempic 0.5mg | Diabetes | Rs 8,000–10,000 |
| Ozempic 1mg | Diabetes | Rs 12,000–15,000 |
| Rybelsus 14mg | Diabetes | Rs 4,000–6,000 |
| Saxenda 3mg | Weight loss | Rs 12,000–15,000 |
| Trulicity 1.5mg | Diabetes | Rs 7,000–9,000 |
Prices are approximate and vary by city and pharmacy. Generic semaglutide from Indian manufacturers may reduce costs — ask your doctor.
Q: Can I take GLP-1 if I have pre-diabetes? Some endocrinologists prescribe GLP-1 to prevent progression from pre-diabetes to T2DM, especially if you are also overweight or obese. This is considered off-label in India. Discuss with an endocrinologist rather than a general physician.
Q: Is Ozempic the same as Wegovy? Both contain semaglutide. Ozempic is approved for diabetes (up to 1mg weekly). Wegovy is the higher-dose formulation (up to 2.4mg weekly) approved specifically for chronic weight management. The active ingredient is identical; the approved doses and indications differ.
Q: Will Indian health insurance cover GLP-1 medications? For diabetes, some corporate health policies cover GLP-1 medications. For obesity, coverage is extremely rare in India. Check your specific policy wording under 'lifestyle diseases' or 'metabolic conditions.' Star Health, HDFC Ergo, and Niva Bupa have different coverage rules — call your insurer directly.
Q: My doctor prescribed Rybelsus instead of Ozempic. Why? Rybelsus is the oral form of semaglutide — no injections required. It is approved for diabetes only. Many patients prefer it over injections. The tradeoff is slightly lower HbA1c reduction compared to injectable semaglutide at equivalent doses, and strict fasting requirements before taking the tablet.
